CooperVision, Inc.; Withdrawal of Color Additive Petition, 52081 [2020-17195]

Download as PDF Federal Register / Vol. 85, No. 164 / Monday, August 24, 2020 / Proposed Rules Overall Burden of the Testing and Component Part Regulations on Small Businesses • To what extent, if any, have children’s product manufacturers increased their use of third party testing in response to the third party testing requirements in section 14 of the CPSA and 16 CFR parts 1107 and 1109? Did third party testing replace other types of testing or quality assurance activities that the manufacturers or importers had been using to ensure that their products complied with the applicable product safety rules? • Is it possible to estimate the overall burden of the testing and component part regulations, perhaps as a percentage of revenue, over and above what businesses would have spent to ensure compliance with the applicable product safety rules in the absence of the testing and component part regulation? Alberta E. Mills, Secretary, Consumer Product Safety Commission. [FR Doc. 2020–16441 Filed 8–21–20; 8:45 am] BILLING CODE 6355–01–P FOR FURTHER INFORMATION CONTACT: Molly A. Harry, Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240–402–1075. SUPPLEMENTARY INFORMATION: In the Federal Register of May 8, 2019 (84 FR 20060), we announced that we had filed a color additive petition (CAP 9C0315), submitted by CooperVision, 5870 Stoneridge Dr., Suite 1, Pleasanton, CA 94588. The petition proposed to amend the color additive regulations in 21 CFR part 73, Listing of Color Additives Exempt from Certification, to provide for the safe use of disperse orange 3 methacrylamide (CAS Reg. 58142–15–7; CAS name 2-propenamide, 2-methyl-N[4-[2-(4-nitrophenyl)diazenyl]phenyl]-) as a color additive in silicone-based hydrogel contact lenses. The color additive was intended to copolymerize with various monomers in the contact lens formulation to produce colored contact lenses. Through this notice, we are announcing that CooperVision has withdrawn the petition without prejudice to a future filing (21 CFR 71.6(c)(2)). Dated: July 31, 2020. Lowell J. Schiller, Principal Associate Commissioner for Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2020–17195 Filed 8–21–20; 8:45 am] Food and Drug Administration BILLING CODE 4164–01–P 21 CFR Part 73 [Docket No. FDA–2019–C–1782] DEPARTMENT OF DEFENSE CooperVision, Inc.; Withdrawal of Color Additive Petition GENERAL SERVICES ADMINISTRATION AGENCY: Food and Drug Administration, HHS. Notification; withdrawal of petition. ACTION: jbell on DSKJLSW7X2PROD with PROPOSALS 48 CFR Part 7 The Food and Drug Administration (FDA or we) is announcing the withdrawal, without prejudice to a future filing, of a color additive petition (CAP 9C0315) proposing that the color additive regulations be amended to provide for the safe use of disperse orange 3 methacrylamide as a color additive in contact lenses. DATES: The color additive petition was withdrawn on June 15, 2020. ADDRESSES: For access to the docket to read background documents or comments received, go to https:// www.regulations.gov and insert the docket number found in brackets in the heading of this document into the ‘‘Search’’ box and follow the prompts, and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. SUMMARY: VerDate Sep<11>2014 16:10 Aug 21, 2020 Jkt 250001 NATIONAL AERONAUTICS AND SPACE ADMINISTRATION [FAR Case 2019–001, Docket No. FAR– 2019–0020, Sequence No. 1] RIN 9000–AN84 Federal Acquisition Regulation: Analysis for Equipment Acquisitions Department of Defense (DoD), General Services Administration (GSA), and National Aeronautics and Space Administration (NASA). ACTION: Proposed rule. AGENCY: DoD, GSA, and NASA are proposing to amend the Federal Acquisition Regulation (FAR) to implement a section of the FAA Reauthorization Act of 2018, which requires, when acquiring equipment, a case-by-case analysis of cost and other factors associated with certain methods of acquisition, including purchase, SUMMARY: PO 00000 Frm 00024 Fmt 4702 Sfmt 4702 52081 short-term rental or lease, long-term rental or lease, interagency acquisition, and, if applicable, acquisition agreements with a State or local government. DATES: Interested parties should submit written comments at the address shown below on or before October 23, 2020 to be considered in the formation of the final rule. ADDRESSES: Submit comments in response to FAR Case 2019–001 to Regulations.gov: https:// www.regulations.gov. Submit comments via the Federal eRulemaking portal by searching for ‘‘FAR Case 2019–001’’. Select the link ‘‘Comment Now’’ that corresponds with FAR Case 2019–001. Follow the instructions provided at the ‘‘Comment Now’’ screen. Please include your name, company name (if any), and ‘‘FAR Case 2019–001’’ on your attached document. If your comment cannot be submitted using https:// www.regulations.gov, call or email the points of contact in the FOR FURTHER INFORMATION CONTACT section of this document for alternate instructions. Instructions: Please submit comments only and cite ‘‘FAR case 2019–001’’ in all correspondence related to this case. All comments received will be posted without change to https:// www.regulations.gov, including any personal and/or business confidential information provided. FOR FURTHER INFORMATION CONTACT: Mr. Michael O. Jackson, Procurement Analyst, at 202–208–4949, or by email at michaelo.jackson@gsa.gov, for clarification of content. For information pertaining to status or publication schedules, contact the Regulatory Secretariat Division at 202–501–4755 or GSARegSec@gsa.gov. Please cite FAR case 2019–001. SUPPLEMENTARY INFORMATION: I. Background On July 16, 2013, DoD, GSA, and NASA published a Request for Information (RFI) in the Federal Register (78 FR 42524) to determine whether there is a distinction between renting and leasing that is useful for the purposes of FAR subpart 7.4. The public comment period closed in September 2013 and 13 respondents provided comments in response to the RFI. A review of the public comments identified that there are differences between renting and leasing in many industries, but there are no standard differences between renting and leasing that span across all industries. As a result of the review, FAR case 2017–017 was opened to clarify the term ‘‘lease’’, as used in the FAR and a proposed rule E:\FR\FM\24AUP1.SGM 24AUP1

Agencies

[Federal Register Volume 85, Number 164 (Monday, August 24, 2020)]
[Proposed Rules]
[Page 52081]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-17195]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 73

[Docket No. FDA-2019-C-1782]


CooperVision, Inc.; Withdrawal of Color Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notification; withdrawal of petition.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or we) is announcing the 
withdrawal, without prejudice to a future filing, of a color additive 
petition (CAP 9C0315) proposing that the color additive regulations be 
amended to provide for the safe use of disperse orange 3 methacrylamide 
as a color additive in contact lenses.

DATES: The color additive petition was withdrawn on June 15, 2020.

ADDRESSES: For access to the docket to read background documents or 
comments received, go to https://www.regulations.gov and insert the 
docket number found in brackets in the heading of this document into 
the ``Search'' box and follow the prompts, and/or go to the Dockets 
Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Molly A. Harry, Center for Food Safety 
and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., 
College Park, MD 20740, 240-402-1075.

SUPPLEMENTARY INFORMATION: In the Federal Register of May 8, 2019 (84 
FR 20060), we announced that we had filed a color additive petition 
(CAP 9C0315), submitted by CooperVision, 5870 Stoneridge Dr., Suite 1, 
Pleasanton, CA 94588. The petition proposed to amend the color additive 
regulations in 21 CFR part 73, Listing of Color Additives Exempt from 
Certification, to provide for the safe use of disperse orange 3 
methacrylamide (CAS Reg. 58142-15-7; CAS name 2-propenamide, 2-methyl-
N-[4-[2-(4-nitrophenyl)diazenyl]phenyl]-) as a color additive in 
silicone-based hydrogel contact lenses. The color additive was intended 
to copolymerize with various monomers in the contact lens formulation 
to produce colored contact lenses. Through this notice, we are 
announcing that CooperVision has withdrawn the petition without 
prejudice to a future filing (21 CFR 71.6(c)(2)).

    Dated: July 31, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-17195 Filed 8-21-20; 8:45 am]
BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.